Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$18.94M+336.81%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Cordonnier
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 127
- Beta
- 2.09
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.27
Financials
CARL has only 11 quarterly periods on file — the charts below show the full history available.
Revenue
$18.94M+336.8%Net Income
$-10.51MEBITDA
$313.0KFree Cash Flow
$-7.48MEPS (diluted)
$-0.39Shares Outstanding (diluted)
27.19M+2.5%Operating Expenses
$25.58MCash & Debt
$89.22MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $50.51M | $-29.63M | $-2.12 |
| 2024 | $27.16M | $-24.26M | $-1.50 |
| 2023 | $13.78M | $-18.90M | $-4.25 |
Valuation
CARLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5d ago·Neutral
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company's next generation techn…
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately.
View source ↗ - Newsglobenewswire.com·20d ago·Positive
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.42 per share
Typical surprise +7.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.39 vs $-0.40beat
- Tue, May 5$-0.32 vs $-0.43beat
- Wed, Feb 25$-0.32 vs $-0.43beat
- Thu, Nov 6$-0.40 vs $-0.45beat
- Thu, Aug 28$-1.47 vs $-1.52beat
- Thu, Jun 26$-1.39 vs $-0.91miss
Estimates and results for CARL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CARL officers and directors.
- Bought
- $51.1m
- Sold
- $2.6m
7 trades
2 trades
- Bertolini Jeffreysold
- Cordonnier Michaelsold
- Presidio Management Group Xii, L.l.c.bought
- B Capital Group Management, L.p.bought
- Sidow Kevinbought
- Mittendorff Robert Iibought
- Root Jonathan Dbought
- Young Philip Mbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CARL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.